After screening at least 50 different cyclodextrins, LLNL researchers found that the drug Subetadex shows enhanced affinities for fentanyl and its analogues.  Subetadex is a smaller version of sugammadex and with a smaller central cavity, allows it to bind extremely well to fentanyl by comparison.  A pharmacokinetic study showed a rapid clearance of this promising candidate from…

Rather than using genes carried by viruses, LLNL researchers have developed an alternative approach of delivering CAR to T-cells in form of proteins that are carried on the surface of nanolipoprotein (NLP) particles. NLPs are naturally occurring molecules that serve as structural mimics of cell membranes.  They can self-assemble and provide a structure or platform for connecting other…

To address shortcomings of current liposome drug delivery systems, the patented innovation uses drug-loaded liposomes containing carbon nanotube porins (CNTPs) inserted into the liposomal membranes for the delivery of the encapsulated drugs. Short CNTPs (10 nm in length) with narrow diameter (0.8 nm) has been demonstrated to facilitate efficient fusion of lipid bilayers resulting in the…

A new approach of developing synthetic antibacterial mineral assemblages can be used as an alternative treatment when traditional antibiotics fail in clinical and agricultural settings. Mineral mixtures can be synthesized with tunable metal release and reactive oxygen species generation that are capable of killing human pathogens and promoting wound healing. One of the key components in the…

The method described in a pending patent application uses a novel thiacrown (dibenzohexathia-18-crown-6) for efficient extraction of ^197m,gHg and ^197gHg from irradiated Pt target foils. The separation of ^197m,gHg and ^197gHg from Pt foils using this novel thiacrown was found to be highly specific. No detectable amount of the Pt foil was seen in the…

Combining the principles of nanotechnology, cell-free protein synthesis and microfluidics, LLNL researchers have developed a reusable, portable programmable system that can create purified, concentrated protein product in vitro in a microfluidic device containing nucleic acids.

LLNL’s high throughput method involves proteome-wide screening for linear B-cell epitopes using native proteomes isolated from a pathogen of interest and convalescent sera from immunized animals.

LLNL scientists developed novel hydrogels, which are biodegradable soft materials synthesized by a water-soluble polymer. Incorporating silver imparts antimicrobial activity to the material at low concentration compared to currently used silver nanoparticles. Our hydrogels are composed of silver ions instead of silver nanoparticles, which eliminates the toxicity concerns of modern silver…

LLNL has developed a novel process of production, isolation, characterization, and functional re-constitution of membrane-associated proteins in a single step. In addition, LLNL has developed a colorimetric assay that indicates production, correct folding, and incorporation of bR into soluble nanolipoprotein particles (NLPs).

LLNL has developed an approach, for formation of NLP/…